APO Research
Talk to an analyst

APO RESEARCH · REPORT

PD-L1 and PIK3CA Testing

PD-L1 Biomarker Testing measures the amount of PDL1 on cancer cells. PDL1 is a protein that helps keep immune cells from attacking nonharmful cells in the body. Normally, the immune system fights foreign substances like viruses and bacteria, and not your own healthy cells. Some cancer cells have high amounts of PDL1. This allows the cancer cells to "trick" the immune system, and avoid being attacked as foreign, harmful substances.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

PD-L1 Biomarker Testing measures the amount of PDL1 on cancer cells. PDL1 is a protein that helps keep immune cells from attacking nonharmful cells in the body. Normally, the immune system fights foreign substances like viruses and bacteria, and not your own healthy cells. Some cancer cells have high amounts of PDL1. This allows the cancer cells to "trick" the immune system, and avoid being attacked as foreign, harmful substances.

Current PD-L1 testing is based on immunohistochemistry (IHC) methods. Immunohistochemistry (IHC) is the process whereby antibodies are used to detect proteins (antigens) in cells within a tissue section (for instance liver, pancreas or the heart).

PD-L1 is a ligand that binds to PD-1 (programmed cell death-1), expressed on activated T cells, to evade anti-tumor responses. PD-L1 plays a role in inhibiting T cell activation and proliferation and has emerged as an important target in cancer treatment. PD-L1 protein detection by immunohistochemistry (IHC) testing is widely used as a predictive biomarker assay for anti–PD-1/PD-L1 therapies.

PIK3CA is a gene that encodes a lipid kinase involved in multiple signaling pathways. These pathways influence cellular functions such as growth, death, and proliferation. PIK3CA mutations activate the PI3K-PTEN-AKT pathway, which is downstream from both the EGFR and the RAS-RAF-MAPK pathways. PIK3CA mutations may cause oncogenic transformation independent of RAS or RAF mutations.

PIK3CA mutations occur in about 15% to 30% of breast, endometrial, and colon cancers. They occur less frequently in lung cancer and other types of cancer. Presence of PIK3CA mutations is associated with poor prognosis and lack of response to specific therapies in patients with breast, endometrial, or colon cancer.

Selected research

Market Outlook & Growth Opportunities

Global PD-L1 and PIK3CA Testing Market Outlook and Growth Opportunities 2026

30 December 2025196 pages

Choose your research edition.

Industry ResearchPD-L1 and PIK3CA Testing Industry Research Report 2026111 pages · $2,950 USDIndustry Growth & TrendsGlobal PD-L1 and PIK3CA Testing Industry Growth and Trends Forecast to 203288 pages · $3,450 USDMarket StructureGlobal PD-L1 and PIK3CA Testing Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032186 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal PD-L1 and PIK3CA Testing Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal PD-L1 and PIK3CA Testing Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

PD-L1 Biomarker Testing measures the amount of PDL1 on cancer cells. PDL1 is a protein that helps keep immune cells from attacking nonharmful cells in the body. Normally, the immune system fights foreign substances like viruses and bacteria, and not your own healthy cells. Some cancer cells have high amounts of PDL1. This allows the cancer cells to "trick" the immune system, and avoid being attacked as foreign, harmful substances.

Current PD-L1 testing is based on immunohistochemistry (IHC) methods. Immunohistochemistry (IHC) is the process whereby antibodies are used to detect proteins (antigens) in cells within a tissue section (for instance liver, pancreas or the heart).

PD-L1 is a ligand that binds to PD-1 (programmed cell death-1), expressed on activated T cells, to evade anti-tumor responses. PD-L1 plays a role in inhibiting T cell activation and proliferation and has emerged as an important target in cancer treatment. PD-L1 protein detection by immunohistochemistry (IHC) testing is widely used as a predictive biomarker assay for anti–PD-1/PD-L1 therapies.

Read the full market overview

PIK3CA is a gene that encodes a lipid kinase involved in multiple signaling pathways. These pathways influence cellular functions such as growth, death, and proliferation. PIK3CA mutations activate the PI3K-PTEN-AKT pathway, which is downstream from both the EGFR and the RAS-RAF-MAPK pathways. PIK3CA mutations may cause oncogenic transformation independent of RAS or RAF mutations.

PIK3CA mutations occur in about 15% to 30% of breast, endometrial, and colon cancers. They occur less frequently in lung cancer and other types of cancer. Presence of PIK3CA mutations is associated with poor prognosis and lack of response to specific therapies in patients with breast, endometrial, or colon cancer.

The classification of PD-L1 and PIK3CA Testing Product includes PD-L1 Testing and PIK3CA Testing. PD-L1 accounted for a share of 80% in the global PD-L1 and PIK3CA Testing Product market.

PD-L1 and PIK3CA Testing Product is widely used in Hospital, Diagnostic Center and Other. In PD-L1 and PIK3CA Testing Product market, the Diagnostic Center holds an important share in terms of Application.

North America is the largest consumption place, with a market share nearly 57% . Following North America, Europe is the second largest consumption place with the market share of 28%.

Market competition is intense. Agilent Technologies, Roche, QIAGEN, Amoy Diagnostics, ACCB Biotech, etc. The top five vendors held 84% of the market share.

This report provides an overview of the global PD-L1 and PIK3CA Testing market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of PD-L1 and PIK3CA Testing and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents PD-L1 and PIK3CA Testing revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global PD-L1 and PIK3CA Testing market.

PD-L1 and PIK3CA Testing Segment by Company

Agilent Technologies

Roche

QIAGEN

EntroGen

Amoy Diagnostics

ACCB Biotech

PD-L1 and PIK3CA Testing Segment by Type

PD-L1 Testing

PIK3CA Testing

PD-L1 and PIK3CA Testing Segment by Application

Hospital

Diagnostic Center

Others

PD-L1 and PIK3CA Testing Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global PD-L1 and PIK3CA Testing status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the PD-L1 and PIK3CA Testing key companies, revenue, market share, and recent developments.

3. To split the PD-L1 and PIK3CA Testing breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions PD-L1 and PIK3CA Testing market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify PD-L1 and PIK3CA Testing significant trends, drivers, influence factors in global and regions.

6. To analyze PD-L1 and PIK3CA Testing competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global PD-L1 and PIK3CA Testing market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of PD-L1 and PIK3CA Testing and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of PD-L1 and PIK3CA Testing.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global PD-L1 and PIK3CA Testing industry.

Chapter 3: Detailed analysis of PD-L1 and PIK3CA Testing company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of PD-L1 and PIK3CA Testing in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of PD-L1 and PIK3CA Testing in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. PD-L1 and PIK3CA Testing Industry Trends Table 2. PD-L1 and PIK3CA Testing Industry Drivers Table 3. PD-L1 and PIK3CA Testing Industry Opportunities and Challenges Table 4. PD-L1 and PIK3CA Testing Industry Restraints Table 5. Global PD-L1 and PIK3CA Testing Revenue by Company (US$ Million) & (2021-2026) Table 6. Global PD-L1 and PIK3CA Testing Revenue Share by Company (2021-2026) Table 7. Global PD-L1 and PIK3CA Testing Company Ranking, (2024-2026) & (US$ Million) Table 8. Global PD-L1 and PIK3CA Testing Key Company Manufacturing Base & Headquarters Table 9. Global PD-L1 and PIK3CA Testing Company, Product Type & Application Table 10. Global PD-L1 and PIK3CA Testing Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global PD-L1 and PIK3CA Testing by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of PD-L1 Testing Table 15. Significant Companies of PIK3CA Testing Table 16. Global PD-L1 and PIK3CA Testing Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global PD-L1 and PIK3CA Testing Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global PD-L1 and PIK3CA Testing Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global PD-L1 and PIK3CA Testing Sales Value Share by Type (2021-2026) Table 20. Global PD-L1 and PIK3CA Testing Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Hospital Table 22. Significant Companies of Diagnostic Center Table 23. Significant Companies of Others Table 24. Global PD-L1 and PIK3CA Testing Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global PD-L1 and PIK3CA Testing Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global PD-L1 and PIK3CA Testing Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global PD-L1 and PIK3CA Testing Sales Value Share by Application (2021-2026) Table 28. Global PD-L1 and PIK3CA Testing Sales Value Share by Application (2027-2032) Table 29. Global PD-L1 and PIK3CA Testing Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global PD-L1 and PIK3CA Testing Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global PD-L1 and PIK3CA Testing Sales Value Share by Region (2021-2026) Table 32. Global PD-L1 and PIK3CA Testing Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global PD-L1 and PIK3CA Testing Sales Value Share by Region (2027-2032) Table 34. Global PD-L1 and PIK3CA Testing Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global PD-L1 and PIK3CA Testing Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global PD-L1 and PIK3CA Testing Sales Value Market Share by Country (2021-2026) Table 37. Global PD-L1 and PIK3CA Testing Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global PD-L1 and PIK3CA Testing Sales Value Market Share by Country (2027-2032) Table 39. Agilent Technologies Company Information Table 40. Agilent Technologies Business Overview Table 41. Agilent Technologies PD-L1 and PIK3CA Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Agilent Technologies PD-L1 and PIK3CA Testing Product Portfolio Table 43. Agilent Technologies Recent Development Table 44. Roche Company Information Table 45. Roche Business Overview Table 46. Roche PD-L1 and PIK3CA Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Roche PD-L1 and PIK3CA Testing Product Portfolio Table 48. Roche Recent Development Table 49. QIAGEN Company Information Table 50. QIAGEN Business Overview Table 51. QIAGEN PD-L1 and PIK3CA Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. QIAGEN PD-L1 and PIK3CA Testing Product Portfolio Table 53. QIAGEN Recent Development Table 54. EntroGen Company Information Table 55. EntroGen Business Overview Table 56. EntroGen PD-L1 and PIK3CA Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. EntroGen PD-L1 and PIK3CA Testing Product Portfolio Table 58. EntroGen Recent Development Table 59. Amoy Diagnostics Company Information Table 60. Amoy Diagnostics Business Overview Table 61. Amoy Diagnostics PD-L1 and PIK3CA Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Amoy Diagnostics PD-L1 and PIK3CA Testing Product Portfolio Table 63. Amoy Diagnostics Recent Development Table 64. ACCB Biotech Company Information Table 65. ACCB Biotech Business Overview Table 66. ACCB Biotech PD-L1 and PIK3CA Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. ACCB Biotech PD-L1 and PIK3CA Testing Product Portfolio Table 68. ACCB Biotech Recent Development Table 69. Research Programs/Design for This Report Table 70. Authors List of This Report Table 71. Secondary Sources Table 72. Primary Sources List of Figures Figure 1. PD-L1 and PIK3CA Testing Product Image Figure 2. Global PD-L1 and PIK3CA Testing Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global PD-L1 and PIK3CA Testing Market Size (2021-2032) & (US$ Million) Figure 4. Global PD-L1 and PIK3CA Testing Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. PD-L1 Testing Image Figure 8. PIK3CA Testing Image Figure 9. Global PD-L1 and PIK3CA Testing Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global PD-L1 and PIK3CA Testing Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global PD-L1 and PIK3CA Testing Sales Value Share by Type (2021-2032) Figure 12. Hospital Image Figure 13. Diagnostic Center Image Figure 14. Others Image Figure 15. Global PD-L1 and PIK3CA Testing Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global PD-L1 and PIK3CA Testing Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global PD-L1 and PIK3CA Testing Sales Value Share by Application (2021-2032) Figure 18. Global PD-L1 and PIK3CA Testing Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global PD-L1 and PIK3CA Testing Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America PD-L1 and PIK3CA Testing Sales Value (2021-2032) & (US$ Million) Figure 21. North America PD-L1 and PIK3CA Testing Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe PD-L1 and PIK3CA Testing Sales Value (2021-2032) & (US$ Million) Figure 23. Europe PD-L1 and PIK3CA Testing Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific PD-L1 and PIK3CA Testing Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific PD-L1 and PIK3CA Testing Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America PD-L1 and PIK3CA Testing Sales Value (2021-2032) & (US$ Million) Figure 27. South America PD-L1 and PIK3CA Testing Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa PD-L1 and PIK3CA Testing Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa PD-L1 and PIK3CA Testing Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • PD-L1 Testing
  • PIK3CA Testing
Applications
  • Hospital
  • Diagnostic Center
  • Others
Companies covered
  • Agilent Technologies
  • Roche
  • QIAGEN
  • EntroGen
  • Amoy Diagnostics
  • ACCB Biotech

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global PD-L1 and PIK3CA Testing Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global PD-L1 and PIK3CA Testing Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 PD-L1 and PIK3CA Testing Market Dynamics
  1. 2.1 PD-L1 and PIK3CA Testing Industry Trends
  2. 2.2 PD-L1 and PIK3CA Testing Industry Drivers
  3. 2.3 PD-L1 and PIK3CA Testing Industry Opportunities and Challenges
  4. 2.4 PD-L1 and PIK3CA Testing Industry Restraints
3 PD-L1 and PIK3CA Testing Market by Company
  1. 3.1 Global PD-L1 and PIK3CA Testing Company Revenue Ranking in 2025
  2. 3.2 Global PD-L1 and PIK3CA Testing Revenue by Company (2021-2026)
  3. 3.3 Global PD-L1 and PIK3CA Testing Company Ranking (2024-2026)
  4. 3.4 Global PD-L1 and PIK3CA Testing Company Manufacturing Base and Headquarters
  5. 3.5 Global PD-L1 and PIK3CA Testing Company Product Type and Application
  6. 3.6 Global PD-L1 and PIK3CA Testing Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global PD-L1 and PIK3CA Testing Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 PD-L1 and PIK3CA Testing Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 PD-L1 and PIK3CA Testing Market by Type
  1. 4.1 PD-L1 and PIK3CA Testing Type Introduction
  2. 4.1.1 PD-L1 Testing
  3. 4.1.2 PIK3CA Testing
  4. 4.2 Global PD-L1 and PIK3CA Testing Sales Value by Type
  5. 4.2.1 Global PD-L1 and PIK3CA Testing Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global PD-L1 and PIK3CA Testing Sales Value by Type (2021-2032)
  7. 4.2.3 Global PD-L1 and PIK3CA Testing Sales Value Share by Type (2021-2032)
5 PD-L1 and PIK3CA Testing Market by Application
  1. 5.1 PD-L1 and PIK3CA Testing Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Diagnostic Center
  4. 5.1.3 Others
  5. 5.2 Global PD-L1 and PIK3CA Testing Sales Value by Application
  6. 5.2.1 Global PD-L1 and PIK3CA Testing Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global PD-L1 and PIK3CA Testing Sales Value by Application (2021-2032)
  8. 5.2.3 Global PD-L1 and PIK3CA Testing Sales Value Share by Application (2021-2032)
6 PD-L1 and PIK3CA Testing Regional Value Analysis
  1. 6.1 Global PD-L1 and PIK3CA Testing Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global PD-L1 and PIK3CA Testing Sales Value by Region (2021-2032)
  3. 6.2.1 Global PD-L1 and PIK3CA Testing Sales Value by Region: 2021-2026
  4. 6.2.2 Global PD-L1 and PIK3CA Testing Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America PD-L1 and PIK3CA Testing Sales Value (2021-2032)
  7. 6.3.2 North America PD-L1 and PIK3CA Testing Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe PD-L1 and PIK3CA Testing Sales Value (2021-2032)
  10. 6.4.2 Europe PD-L1 and PIK3CA Testing Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific PD-L1 and PIK3CA Testing Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific PD-L1 and PIK3CA Testing Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America PD-L1 and PIK3CA Testing Sales Value (2021-2032)
  16. 6.6.2 South America PD-L1 and PIK3CA Testing Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa PD-L1 and PIK3CA Testing Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa PD-L1 and PIK3CA Testing Sales Value Share by Country, 2025 VS 2032
7 PD-L1 and PIK3CA Testing Country-level Value Analysis
  1. 7.1 Global PD-L1 and PIK3CA Testing Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global PD-L1 and PIK3CA Testing Sales Value by Country (2021-2032)
  3. 7.2.1 Global PD-L1 and PIK3CA Testing Sales Value by Country (2021-2026)
  4. 7.2.2 Global PD-L1 and PIK3CA Testing Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt PD-L1 and PIK3CA Testing Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt PD-L1 and PIK3CA Testing Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt PD-L1 and PIK3CA Testing Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Agilent Technologies
  2. 8.1.1 Agilent Technologies Company Information
  3. 8.1.2 Agilent Technologies Business Overview
  4. 8.1.3 Agilent Technologies PD-L1 and PIK3CA Testing Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Agilent Technologies PD-L1 and PIK3CA Testing Product Portfolio
  6. 8.1.5 Agilent Technologies Recent Developments
  7. 8.2 Roche
  8. 8.2.1 Roche Company Information
  9. 8.2.2 Roche Business Overview
  10. 8.2.3 Roche PD-L1 and PIK3CA Testing Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Roche PD-L1 and PIK3CA Testing Product Portfolio
  12. 8.2.5 Roche Recent Developments
  13. 8.3 QIAGEN
  14. 8.3.1 QIAGEN Company Information
  15. 8.3.2 QIAGEN Business Overview
  16. 8.3.3 QIAGEN PD-L1 and PIK3CA Testing Revenue and Gross Margin (2021-2026)
  17. 8.3.4 QIAGEN PD-L1 and PIK3CA Testing Product Portfolio
  18. 8.3.5 QIAGEN Recent Developments
  19. 8.4 EntroGen
  20. 8.4.1 EntroGen Company Information
  21. 8.4.2 EntroGen Business Overview
  22. 8.4.3 EntroGen PD-L1 and PIK3CA Testing Revenue and Gross Margin (2021-2026)
  23. 8.4.4 EntroGen PD-L1 and PIK3CA Testing Product Portfolio
  24. 8.4.5 EntroGen Recent Developments
  25. 8.5 Amoy Diagnostics
  26. 8.5.1 Amoy Diagnostics Company Information
  27. 8.5.2 Amoy Diagnostics Business Overview
  28. 8.5.3 Amoy Diagnostics PD-L1 and PIK3CA Testing Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Amoy Diagnostics PD-L1 and PIK3CA Testing Product Portfolio
  30. 8.5.5 Amoy Diagnostics Recent Developments
  31. 8.6 ACCB Biotech
  32. 8.6.1 ACCB Biotech Company Information
  33. 8.6.2 ACCB Biotech Business Overview
  34. 8.6.3 ACCB Biotech PD-L1 and PIK3CA Testing Revenue and Gross Margin (2021-2026)
  35. 8.6.4 ACCB Biotech PD-L1 and PIK3CA Testing Product Portfolio
  36. 8.6.5 ACCB Biotech Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst